Hospital
ST Josephs Hospital of the Hospital Sisters of the Third Order of ST F
ST Josephs Hospital of the Hospital Sisters of the Third Order of ST F was paid $4.46M by Medicaid between Jan 2018 and Mar 2024, across 112 billing codes. Its largest line is H0018, Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem — 30% of everything it billed.
33Billing provider infoST JOSEPHS HOSPITAL OF THE HOSPITAL SISTERS OF THE THIRD ORDER OF ST F
CHIPPEWA FALLS, WI 54729
CHIPPEWA FALLS, WI 54729
33aNPI1164429908assigned 07/07/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.46M
24GClaims163,538
24DCodes billed112
24AFirst – last monthJan 2018 – Mar 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#27 of 60
Median peer was paid$2.90M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,291 | $713K | |
| 2019 | 24,013 | $504K | |
| 2020 | 23,638 | $434K | |
| 2021 | 26,112 | $470K | |
| 2022 | 32,849 | $1.01M | |
| 2023 | 25,244 | $1.17M | |
| 2024incomplete | 3,391 | $158K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | 30% | 7,969 | 478 | $1.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 10,146 | 8,518 | $578K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 7.2% | 7,491 | 2,951 | $321K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.0% | 3,842 | 3,351 | $269K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.5% | 6,145 | 5,154 | $245K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.0% | 2,717 | 1,932 | $223K |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.3% | 546 | 428 | $190K |
| 80053 | Comprehensive metabolic panel | 3.9% | 7,667 | 5,974 | $174K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 3,125 | 2,586 | $99K |
| 87631 | 1.9% | 815 | 679 | $84K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 2,200 | 1,203 | $83K |
| 97597 | 1.8% | 3,809 | 1,909 | $81K |
100 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 2,041 | $78K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 2,265 | $63K |
| 80306 | 1.3% | 1,293 | $58K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 10,232 | $52K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 1,385 | $52K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 1,105 | $50K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 814 | $47K |
| 82948 | <1% | 3,735 | $33K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,153 | $30K |
| 81025 | <1% | 1,936 | $28K | |
| 84484 | <1% | 3,261 | $24K | |
| 81000 | <1% | 3,551 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,625 | $15K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 150 | $15K |
| 81002 | <1% | 2,186 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 391 | $14K |
| 29580 | <1% | 506 | $14K | |
| 83605 | <1% | 1,605 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 709 | $11K |
| 83690 | <1% | 2,251 | $11K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 248 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 192 | $10K |
| 86140 | <1% | 2,163 | $9K | |
| 11045 | <1% | 178 | $9K | |
| 87077 | <1% | 741 | $8K | |
| 83735 | <1% | 2,076 | $8K | |
| 87088 | <1% | 458 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 484 | $6K |
| 87040 | <1% | 1,307 | $6K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 108 | $6K |
| 85610 | <1% | 2,021 | $5K | |
| 87186 | <1% | 977 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,579 | $4K |
| 83880 | <1% | 358 | $4K | |
| 87430 | <1% | 94 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,618 | $3K |
| 85730 | <1% | 1,063 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,276 | $3K |
| 85378 | <1% | 597 | $3K | |
| 87070 | <1% | 178 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,210 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,678 | $2K |
| 87205 | <1% | 467 | $1K | |
| 74018 | <1% | 89 | $1K | |
| 84145 | <1% | 51 | $922.12 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,739 | $886.04 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 29 | $768.67 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $715.04 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,809 | $593.70 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 35 | $550.79 |
| 84703 | <1% | 90 | $536.38 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 127 | $495.05 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $463.41 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $463.41 |
| 80076 | <1% | 77 | $395.63 | |
| 82550 | <1% | 91 | $339.71 | |
| 87807 | <1% | 15 | $235.42 | |
| 87075 | <1% | 31 | $185.34 | |
| 82150 | <1% | 35 | $158.89 | |
| 73610 | <1% | 13 | $100.78 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,358 | $78.27 |
| 86901 | <1% | 27 | $68.81 | |
| 86900 | <1% | 27 | $68.81 | |
| 80050 | General health panel | <1% | 164 | $41.03 |
| 86850 | <1% | 13 | $38.42 | |
| 85652 | <1% | 16 | $17.32 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,993 | $12.50 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,028 | $8.82 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,651 | $4.60 |
| J3490 | Unclassified drugs | <1% | 2,584 | $3.30 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,537 | $2.42 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 176 | $0.35 |
| J2704 | Injection, propofol, 10 mg | <1% | 922 | $0.18 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 783 | $0.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,710 | $0.10 |
| A9270 | Non-covered item or service | <1% | 3,095 | $0.08 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,427 | $0.03 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 850 | $0.03 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 75 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 178 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 96 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 45 | $0.00 |
| 96376 | 0% | 184 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 98 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 18 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 69 | $0.00 |
| 94760 | 0% | 21 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 28 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 14 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 18 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 174 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 827 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 22 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 43 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 80 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 15 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 65 | $0.00 |
| 73630 | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWAGNER, JOHN (CEO)
| Provider | Location | Paid |
|---|---|---|
| ST. Nicholas Hospital-Sisters of the Third Order of ST Francis | Sheboygan, WI | $853K |
| ST Josephs Hospital of the Hospital Sisters of the Third Order of ST F | Chippewa Falls, WI | $516K |
| ST Josephs Hospital of the Hospital Sisters of the Third Order of ST F | Chippewa Falls, WI | $210K |
| ST. Josephs Hospital of the Hospital Sisters of the Third Order of ST | Chippewa Falls, WI | $162K |
| WGM Obstetrics and Gynecology,pc | East Northport, NY | $92K |
| ST. Joseph's Hospital of the Hospital Sisters of the 3RD Order of ST F | Chippewa Falls, WI | $27K |
| ST Josephs Hospital of the Hospital Sisters of the 3RD Order of ST Fra | Eau Claire, WI | $12K |
| John Wagner Psychological Services LLC | Cincinnati, OH | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.